This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Webinars/Videos
Infographics
Articles
Case Studies
Forum
Faculty
Unblocked
Webinar
Stay up to date

Articles

The Potential Clinical Benefit of Lowering Lipoprotein(a)

Ference BA

Journal:

JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5333

Abstract

You might also like...

Running time: 18 minutes
Webinars/Videos
Peer-to-Peer Discussion: Novel lipid-lowering therapies
Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.
To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.
Ference BA
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5333
View
- Share
Infographics
Therapeutic Management of Dyslipidaemia: New Strategies
Novel pharmacological interventions targeting lipids can lower the incidence of dyslipidaemia triggered cardiovascular events. Check out and download our latest infographic providing insights into evolution of lipid-lowering therapeutics and status of novel therapeutics highlighting their development, safety, and efficacy.
Ference BA
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5333
View
- Share
Case Studies
Quiz of the month – January 2023
Poll Question
Ference BA
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5333
Take
- Share

How would you rate this content?

© John Wiley & Sons, Ltd. All rights reserved.
Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.